See more : Capstone Infrastructure Corporation (CPOIF) Income Statement Analysis – Financial Results
Complete financial analysis of Arvinas, Inc. (ARVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arvinas, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- CITY CROPS AGRO LIMITED (CCAL.BO) Income Statement Analysis – Financial Results
- Ziff Davis, Inc. (JCOM) Income Statement Analysis – Financial Results
- Zhejiang Xinao Textiles Inc. (603889.SS) Income Statement Analysis – Financial Results
- Itaúsa S.A. (ITSA4.SA) Income Statement Analysis – Financial Results
- CG-VAK Software and Exports Limited (CGVAK.BO) Income Statement Analysis – Financial Results
Arvinas, Inc. (ARVN)
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 78.50M | 131.40M | 46.70M | 21.80M | 42.98M | 14.32M | 7.58M | 6.67M |
| Cost of Revenue | 0.00 | 8.20M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 78.50M | 123.20M | 40.70M | 21.80M | 42.98M | 14.32M | 7.58M | 6.67M |
| Gross Profit Ratio | 100.00% | 93.76% | 87.15% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 379.70M | 315.00M | 180.40M | 108.36M | 67.19M | 45.19M | 28.79M | 19.94M |
| General & Administrative | 100.30M | 79.60M | 61.60M | 38.30M | 27.31M | 12.93M | 3.55M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.30M | 79.60M | 61.60M | 38.30M | 27.31M | 12.93M | 3.55M | 3.20M |
| Other Expenses | 0.00 | 200.00K | 2.50M | 2.00M | 1.44M | 102.73K | 554.16K | 1.66M |
| Operating Expenses | 480.00M | 394.60M | 242.00M | 146.66M | 94.50M | 58.13M | 32.34M | 23.14M |
| Cost & Expenses | 480.00M | 394.60M | 242.00M | 146.66M | 94.50M | 58.13M | 32.34M | 23.14M |
| Interest Income | 38.80M | 12.20M | 4.30M | 5.53M | 5.91M | 2.32M | 201.39K | 427.77K |
| Interest Expense | 0.00 | 12.00M | 100.00K | 65.00K | 85.57K | 57.44K | 50.36K | 67.40K |
| Depreciation & Amortization | 6.70M | 8.20M | 6.00M | 4.02M | 2.25M | 706.00K | 347.40K | 436.33K |
| EBITDA | -394.80M | -256.90M | -183.60M | -117.60M | -67.95M | -40.72M | -23.65M | -13.93M |
| EBITDA Ratio | -502.93% | -200.30% | -418.20% | -572.69% | -119.89% | -305.80% | -312.15% | -209.16% |
| Operating Income | -401.50M | -263.20M | -195.30M | -124.86M | -51.52M | -43.80M | -24.76M | -16.47M |
| Operating Income Ratio | -511.46% | -200.30% | -418.20% | -572.69% | -119.89% | -305.80% | -326.70% | -246.95% |
| Total Other Income/Expenses | 37.60M | 12.20M | -2.60M | 1.50M | -18.79M | 2.32M | 711.06K | 2.03M |
| Income Before Tax | -363.90M | -251.00M | -191.00M | -119.33M | -70.29M | -41.48M | -24.05M | -14.44M |
| Income Before Tax Ratio | -463.57% | -191.02% | -408.99% | -547.35% | -163.56% | -289.59% | -317.32% | -216.49% |
| Income Tax Expense | 900.00K | 20.90M | -7.80M | -7.55M | -8.16M | 2.38M | 604.52K | -87.41K |
| Net Income | -367.30M | -271.90M | -183.20M | -111.79M | -62.13M | -41.48M | -24.05M | -14.35M |
| Net Income Ratio | -467.90% | -206.93% | -392.29% | -512.74% | -144.57% | -289.59% | -317.32% | -215.18% |
| EPS | -6.62 | -5.11 | -3.66 | -2.83 | -1.89 | -4.40 | -1.16 | -0.80 |
| EPS Diluted | -6.62 | -5.11 | -3.66 | -2.83 | -1.89 | -4.40 | -1.16 | -0.80 |
| Weighted Avg Shares Out | 55.50M | 53.20M | 50.00M | 39.53M | 32.93M | 9.42M | 20.73M | 17.88M |
| Weighted Avg Shares Out (Dil) | 55.50M | 53.20M | 50.00M | 39.53M | 32.93M | 9.42M | 20.73M | 17.88M |
Arvinas, Inc. (ARVN) Q3 2024 Earnings Call Transcript
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals +
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
Source: https://incomestatements.info
Category: Stock Reports